Abicipar pegol

Abicipar pegol (AGN-150998, MP0112) is an anti-VEGF DARPin molecule, a novel class of small proteins containing ankyrin repeat domains engineered to bind with high specificity and affinity to target proteins. Abicipar pegol effectively inhibits angiogenesis and vascular permeability and is used in the study of diseases related to ocular inflammation by intravitreal injection, reducing mean retinal thickness and leakage area[1][2].

Research Areas >> Cardiovascular Disease

Research Areas >> Inflammation/Immunology

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> VEGFR

[1]. Gerard A Rodrigues, et al. Functional Characterization of Abicipar-Pegol, an Anti-VEGF DARPin Therapeutic That Potently Inhibits Angiogenesis and Vascular Permeability. Invest Ophthalmol Vis Sci. 2018 Dec 3;59(15):5836-5846.  

[2]. Sepehr Bahadorani, et al. Recent advances in the management and understanding of macular degeneration. F1000Res. 2017 Apr 20;6:519.